Scientists probe Psilocybin's brain mechanism in tiny new study
NCT ID NCT07565493
First seen May 07, 2026
Summary
This early-phase study at Johns Hopkins University will give 18 healthy volunteers psilocybin (the active compound in magic mushrooms) along with either a drug that blocks the 5-HT1a receptor (pindolol) or a placebo. Researchers will use questionnaires and brain wave recordings (EEG) to see how blocking this receptor changes the psychedelic experience and its effects on sleep and dreaming. The goal is purely to understand the brain mechanisms behind psilocybin's effects, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHEDELIC EFFECTS IN HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Psychedelics and Consciousness Research
Baltimore, Maryland, 21224-5010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin and pindolol
What this could lead to
If successful, this could help scientists understand how psilocybin works in the brain, potentially leading to better-targeted therapies for mental health conditions.
What could go wrong
This is a very small, early-phase study in healthy volunteers, not patients. It is designed to measure brain activity and subjective experiences, not to test a treatment, so direct medical benefits are unlikely.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.